



CORONAVÍRUS • COVID - 19 • VACINA

Assessment of Vaccines and Medicines Using Emergency Use Authorization: Anvisa perspectives

Gustavo Mendes Lima Santos

Gerência-Geral de Medicamentos e Produtos Biológicos



CORONAVÍRUS • COVID - 19 • VACINA

Emergency Use Authorization


- **Requested by:** Holder with Authorization at Anvisa
- **Required Data:** Critical Quality/Safety/Efficacy Points and Approval by other agencies.
- **Reviewed by:** Anvisa
- **Deadline:** 7 working days (Development in Brazil or Technical Report of reference agency) and up to 30 days (Development abroad or absence of report)
- **Legislation:** RDC no. 475 of 10 March 2021



CORONAVÍRUS • COVID - 19 • VACINA

**What is checked to assess a vaccine or
medicine by EUA?**

General Office of Medicines and Biological Products




Biotechnology



- **Formulation;**
- **Production;**
- **Quality Control;**

Efficacy and Safety



- **Non-Clinical Studies;**
- **Clinical Studies;**

General Office of Monitoring

```
graph TD; A[Main Evaluation Aspects] --- B[Pharmacovigilance Plan];
```

Main Evaluation Aspects

Pharmacovigilance Plan

Pharmacovigilance Plan



“identification, assessment, understanding and prevention of adverse effects or any problems related to the use of.”

General Office of Inspections

```
graph TD; A[Main Evaluation Aspects] --> B[Good Manufacturing Practices];
```

Main Evaluation Aspects

Good Manufacturing
Practices

Good Manufacturing Practices



- *Quality System;*
- *Robustness of the Production Process;*



CORONAVÍRUS • COVID - 19 • VACINA

Types of Vaccine and Drug Approvals against COVID-19

Conditional Marketing Approval

- **Requested by:** Holder with Authorization at Anvisa
- **Required Data:** Complete Studies of Quality, Safety and Efficacy
- **Reviewed by:** Anvisa
- **Deadline:** Up to 60 days (Term of Commitment)
- **Legislation:** RDC No 415 of 26 August 2020



Exceptional and Temporary Import

- **Requested by:** Ministry of Health, States, Municipalities and Federal District
- **Required Data:** Authorization by Foreign Agency, Declaration of Non-compliance with the National Plan for The Operationalization of Vaccination against Covid-19
- **Reviewed by:** Anvisa
- **Deadline:** 7 working days or 30 days (in the absence of technical report of the foreign agency)
- **Legislation:** RDC no. 476 of 10 March 2021



CORONAVÍRUS • COVID - 19 • VACINA

Trends and Legacy

Trends and Legacy for Emergency Use Authorization

- ✓ **Improvement of Reliance Strategies;**
- ✓ **Innovative Administrative Tools;**
- ✓ **Focusing on critical aspects of technical evaluation;**
- ✓ **Closer approach with products developers.**

Agência Nacional de Vigilância Sanitária - Anvisa



www.gov.br/anvisa